FC
RARE icon

Finepoint Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Finepoint Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-203,200
Closed -$12.1M – 59
2022
Q2 		$12.1M Buy
+203,200
New +$12.5M 4.19% 15

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Finepoint Capital's RARE Position: Q3 2022 in Review

Finepoint Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2022, closing a stake of 203,200 shares — an estimated $12.1M sold.

Finepoint Capital first reported a position in RARE in Q2 2022 and held it in 1 quarter. The position peaked at $12.1M in Q2 2022. 232 funds tracked by Wall St. Rank hold RARE as of Q3 2022.

  • Finepoint Capital reported no remaining Ultragenyx Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • Finepoint Capital sold 203,200 Ultragenyx Pharmaceutical shares in Q3 2022, an estimated $12.1M.
  • Finepoint Capital first reported a position in Ultragenyx Pharmaceutical in Q2 2022 and held it in 1 quarter.
  • Finepoint Capital's Ultragenyx Pharmaceutical position peaked at $12.1M in Q2 2022.
  • 232 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2022.

Based on Finepoint Capital's 13F filing for Q3 2022, filed 10 Nov 2022.